Related Experiment Video
Updated: Jun 23, 2025

A Human Ex Vivo Atherosclerotic Plaque Model to Study Lesion Biology
Published on: May 6, 2014
Interplay between epigenetic mechanisms and transcription factors in atherosclerosis
Misbah Aziz1, Karin Am Jandeleit-Dahm2, Abdul Waheed Khan1
1Department of Diabetes, Central Clinical School, Monash University, Melbourne, Australia.
Insights
Atherosclerosis, a key factor in cardiovascular diseases (CVD), involves gene regulation by transcription factors and epigenetics. Understanding their crosstalk offers novel therapeutic strategies for CVD.
Area of Science:
- Cardiovascular Science
- Molecular Biology
- Genetics
Background:
- Cardiovascular diseases (CVD) are the leading global cause of mortality.
- Atherosclerosis, a vascular inflammatory disease, is a major contributor to CVD.
- Gene expression regulation by transcription factors and epigenetic mechanisms is crucial in atherosclerosis development.
Purpose of the Study:
- To review the underappreciated crosstalk between transcription factors and epigenetic mechanisms in atherosclerosis.
- To highlight novel therapeutic strategies targeting these mechanisms for CVD treatment.
Main Methods:
- Literature review of studies on gene regulation in atherosclerosis.
- Analysis of the interaction between transcription factors and epigenetic modifiers.
- Exploration of potential therapeutic targets in atherosclerotic CVD.
Main Results:
- Transcription factors and epigenetic mechanisms play fundamental roles in atherosclerosis.
- Crosstalk between these factors is critical but understudied in CVD.
- Chromatin remodeling offers potential therapeutic avenues for CVD.
Conclusions:
- Understanding the interplay between transcription factors and epigenetics is key to developing novel CVD therapeutics.
- Targeting epigenetic modifiers and transcription factors holds promise for combating atherosclerotic CVD.
Abstract:
Cardiovascular diseases (CVD), including coronary heart disease and stroke, comprise the number one cause of mortality worldwide. A major contributor to CVD is atherosclerosis, which is a low-grade inflammatory disease of vasculature that involves a pathological build-up of plaque within the arterial walls. Studies have shown that regulation of gene expression via transcription factors and epigenetic mechanisms play a fundamental role in transcriptomic changes linked to the development of atherosclerosis. Chromatin remodeling is a reversible phenomenon and studies have supported the clinical application of chromatin-modifying agents for the prevention and treatment of CVD. In addition, pre-clinical studies have identified multiple transcription factors as potential therapeutic targets in combating atherosclerotic CVD. Although interaction between transcription factors and epigenetic mechanisms facilitate gene regulation, a limited number of studies appreciate this crosstalk in the context of CVD. Here, we reviewed this gene regulatory mechanism underappreciated in atherosclerosis, which will highlight the mechanisms underlying novel therapeutics targeting epigenetic modifiers and transcription factors in atherosclerosis.
Related Concept Videos
Epigenetic Regulation
General Transcription Factors
Transcription Factors
RNA Polymerase II Accessory Proteins
Master Transcription Regulators
Co-activators and Co-repressors

